-
Starc takes 5-11 to leave Bangladesh reeling in 2nd Test
-
Nakashima pounds Fritz, Bejlek beats Keys in Cincinnati upsets
-
Injured Rune withdraws from US Open
-
Canadian negotiator says 'more work to do' on US trade deal
-
Nakashima knocks out Fritz to reach Cincinnati semi-finals
-
'Solid' Clark takes solo lead at BMW Championship
-
Ukraine says 'cynical' Russian strike on shopping centre killed 16
-
Arteta hails Arsenal's desire after perfect start to title defence
-
TikTok to pay $400 mn settlement in US children's privacy case
-
Betis down Real Sociedad in La Liga opener
-
MLS fines Messi for striking an opponent
-
Mexican governor resumes job despite US drug charges
-
Gouiri double fires Marseille past Strasbourg in Ligue 1 opener
-
Arsenal rout Coventry to open Premier League season in style
-
Mavericks buy out Thompson, now reportedly bound for Heat
-
Giant-killer Bejlek overhauls Keys to reach Cincinnati semi-finals
-
England v Pakistan first Test: Three talking points
-
Man Utd agree deal for Brighton midfielder Baleba: reports
-
US, Canada push to seal trade deal as deadline nears
-
Werro wins Lausanne 800m, well off world record pace
-
One dead, three wounded after sword attack at Swedish high school
-
China mulls bid to host 2028 UN climate talks: sources
-
Ukraine says 'cynical' Russian strike on shopping centre killed 15
-
Jones becomes third Englishman to join Inter this summer
-
US Supreme Court allows White House ballroom construction for now
-
Mexican governor wanted on US drug charges returns to job
-
Root hails emerging fast bowlers as England thrash Pakistan
-
Bolivia's Paz forced to fire economy minister in mid-crisis
-
Brazil's Lula urges tariffs resolution in call with Trump
-
A-Rod ups T-Wolves stake in $4.5bn ownership change
-
Ukraine says 'cynical' Russian strike on shopping centre killed 14
-
UK court orders Prince Harry, others to pay Daily Mail initial £9.5mn
-
Heatwave-hit Europe logs over 30,000 excess summer deaths: first figures
-
'Grateful' ex-world champion Alaphilippe retires from cycling
-
Give LIV Golf 'one more shot,' says DeChambeau
-
US, Canada work to wrap up trade deal ahead of looming deadline
-
Duplantis hits the high notes for athletics anthem
-
Malaysia's JDT claim unbeaten run world record
-
Malaysia's JDT claims unbeaten run world record
-
At least 2 teens seriously wounded in sword attack at Swedish school
-
Bolivian economy minister fired after Congress vote
-
Popular forest near Paris to reopen after wildfire
-
Russell roars to Dutch GP sprint pole, Antonelli fifth
-
UN holds second informal poll of secretary-general candidates
-
Russell takes pole for Dutch GP sprint
-
Shakhtar Donetsk to play Champions League home games at Chelsea
-
England start life after Bazball with rout of Pakistan
-
Arsenal sign Villa centre-back Konsa as champions bolster defence
-
'Duck run' pest control catching on in S.Africa's winelands
-
The 'hedgehogs' leading Poland's defences on Russian border
Pfizer completes Metsera acquisition in deal worth up to $10 bn
US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.
The approval from Metsera's shareholders opens the door for Pfizer to make inroads into the fast-growing market for weight loss drugs.
Metsera, a US company specializing in obesity treatments, had been the subject of escalating offers from Pfizer and Danish challenger Novo Nordisk, which makes the weight loss drug Wegovy and Ozempic, a diabetes medication with weight loss benefits.
Pfizer said in a statement that its acquisition was successfully completed.
It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.
This involved $65.60 per share in cash, and an additional $20.65 per share linked to the success of its drug pipeline.
"By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it," said Pfizer chief executive Albert Bourla.
"We look forward to combining Metsera's innovative portfolio with our global development, manufacturing and commercial infrastructure," he added.
The potential sale of Metsera to Novo Nordisk had drawn scrutiny over potential antitrust implications.
L.AbuTayeh--SF-PST